Did Wolfe Research set a price target for DHR?

No, Wolfe Research did not assign a price target after the downgrade.

Why did Wolfe Research downgrade Danaher?

Due to similar growth outlook to Thermo Fisher and lack of clear catalysts for outperformance.

Wolfe Research Downgrades Danaher (DHR) to Peer Perform

Wolfe Research downgraded Danaher Corporation (DHR) to Peer Perform from Outperform on June 1, without assigning a price target, noting that growth prospects are similar to rival Thermo Fisher.

June 9, 2026

1 min read

Source: Insider Monkey

Wolfe Research downgraded Danaher Corporation (NYSE:DHR) to Peer Perform from Outperform on June 1, without assigning a price target, after assuming coverage of the stock.

Rating Change

Previous Rating	New Rating
Outperform	Peer Perform

Analyst Rationale

Analysts at Wolfe Research stated that growth forward and backward is similar for Danaher, and that Thermo Fisher Scientific (NYSE:TMO) is a comparable investment alternative. The report did not identify any immediate catalysts for outperformance.

Context

The downgrade follows Wolfe Research's earlier initiation of Danaher with an Outperform rating. Meanwhile, Thermo Fisher continues to receive higher ratings from some other analysts. DHR shares are currently trading near historical levels.

Conclusion

The downgrade reflects a neutral near-term outlook for the stock, with analysts not expecting outperformance relative to peers in the healthcare sector.

Frequently Asked Questions

Wolfe Research downgraded Danaher from Outperform to Peer Perform (neutral).

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.